Biotech RadarJobs updated

COMPANY

Avalo Therapeutics

HQ: Wayne, PA source · avalotx.com ↗

Clinical Phase 2

Location: Wayne, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Major Depressive Disorder Hidradenitis Suppurativa Non-Eosinophilic Asthma Multiple Myeloma Crohn Disease Ulcerative Colitis Lymphatic Malformation Chronic Refractory Cough Acute Cough FP01 CERC-301 AVTX-002 AEVI-007 MDGN-002 CERC-006

$375.0MRaised (2 yrs)10Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $375M (total, as published), announced May 6, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa source ↗
  3. Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. source ↗
  4. Trial start Phase 1: A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations source ↗
  5. Trial start 1: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma source ↗
  6. Trial start Phase 1: Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis source ↗
  7. Trial start Phase 2: A Study of Intermittent Doses of CERC-301 in MDD source ↗
  8. Trial start Phase 2: A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despit source ↗
  9. Trial start Phase 2: An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough source ↗
  10. Trial start Phase 2: Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection source ↗
  11. Trial start Phase 1: A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers source ↗

Funding

Raised: $375.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT06603077A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaPhase 2CompletedSep 16, 2024Feb 23, 2026 (actual)
NCT05288504A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.Phase 2CompletedFeb 24, 2022May 11, 2023 (actual)
NCT04671251Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma1CompletedDec 15, 2020Mar 30, 2022 (actual)
NCT03169894Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative ColitisPhase 1TerminatedJul 14, 2017Sep 14, 2021 (actual)
NCT04994002A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsPhase 1WithdrawnSep 3, 20212022-06 (estimated)
NCT01941043A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant TreatmentPhase 2Completed2013-112014-09 (actual)
NCT02459236A Study of Intermittent Doses of CERC-301 in MDDPhase 2Completed2015-062016-09 (actual)
NCT01703923An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory CoughPhase 2Completed2012-112013-09 (actual)
NCT01597349Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract InfectionPhase 2Completed2012-052012-09 (actual)
NCT01579526A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy VolunteersPhase 1Completed2012-042012-04 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback